Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
Hospices Civils de Lyon · Université Claude Bernard Lyon 1 · +17 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
513
total citations
- FWCI
- 40.17
- Percentile
- 100%
- References
- 30
Citations per year
Authors
17- GSGilles SallesCorresponding
Hospices Civils de Lyon, Université Claude Bernard Lyon 1
- JDJohannes Duell
- EGEva González‐Barca
Institut Català d'Oncologia, Institut d'Investigació Biomédica de Bellvitge, Duran i Reynals Hospital
- OTOlivier Tournilhac
Centre Hospitalier Universitaire de Clermont-Ferrand
- WJWojciech Jurczak
The Maria Sklodowska-Curie National Research Institute of Oncology
Topics & keywords
Topics
Keywords
- Lenalidomide
- Diffuse large B-cell lymphoma
- Refractory (planetary science)
- Medicine
- Lymphoma
- Oncology
- Internal medicine
- Multiple myeloma
No related works found for this paper.